Female sexual dysfunction in anti-synthetase syndrome
- 1Universidade de São Paulo, Faculdade de Medicina, Division of Rheumatology - São Paulo (SP), Brazil.
- 2Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Division of Obstetrics and Gynecology - São Paulo (SP), Brazil.
Abstract
Objective
Sexual dysfunction has not been investigated in women with anti-synthetase syndrome. The aim of this study was to determine the prevalence of sexual dysfunction in women with anti-synthetase syndrome compared with healthy controls (CTR), to evaluate associated clinical factors, and to assess the effect of cognitive behavioral therapy on sexual function and related outcomes.Methods
This single-center study included a cross-sectional evaluation conducted between March and August 2023 and a prospective interventional phase. Thirty-three women with anti-synthetase syndrome and 31 CTR were included. Sexual function, sexual distress, quality of life, fatigue, depression, body image, physical activity, and disease-related parameters were assessed using validated questionnaires. Multivariate logistic regression was used to identify factors independently associated with sexual dysfunction. Patients with anti-synthetase syndrome and sexual dysfunction were invited to participate in group-based cognitive behavioral therapy, with up to 90 days' follow-up.Results
Groups were comparable with respect to age and marital status. Sexual dysfunction prevalence was significantly higher in the anti-synthetase syndrome group than in CTR (81.8 vs. 51.6%; p=0.016). Anti-synthetase syndrome was independently associated with sexual dysfunction (OR 4.11; 95%CI 1.20-15.78). Within the anti-synthetase syndrome cohort, patients with and without sexual dysfunction were similar across most variables, except for prednisone use, which occurred only in patients with sexual dysfunction. Six patients completed cognitive behavioral therapy, showing improvements in sexual distress, sexual function-particularly arousal-and fatigue at 90 days.Conclusion
Sexual dysfunction is highly prevalent in women with anti-synthetase syndrome and appears intrinsically associated with the disease. Cognitive behavioral therapy represents a promising non-pharmacological strategy to improve sexual function, distress, and fatigue in this population.
Related
- Sexual function problems, sexual distress, and operationally defined female sexual dysfunction among women with infertility in southern Iran: a cross-sectional study
- Female Sexual Dysfunction Across the Female Lifespan: The Impact of Menopause, Pelvic Floor Disorders, and Pelvic Surgery
- Clinical characteristics of anti-Ro52/TRIM21-positive versus anti-Ro52/TRIM21-negative patients with anti-synthetase syndrome: a retrospective cohort study
- Tocilizumab in refractory anti-synthetase syndrome-associated interstitial lung disease:a phenotype-stratified cohort study
- A comparison of clinical phenotype and outcomes in anti- melanoma differentiation-associated protein 5 dermatomyositis and anti-synthetase syndrome in a multiethnic cohort in Singapore
BibTeX
@article{silva2026female,
title = {{Female sexual dysfunction in anti-synthetase syndrome}},
author = {Lorenza Rosa Silvério da Silva and Theo Lerner and Elsa Aida Gay de Pereyra and Alexandre Moura Dos Santos and Samuel Katsuyuki Shinjo},
journal = {Revista da Associacao Medica Brasileira (1992)},
year = {2026},
month = oct,
doi = {10.1590/1806-9282.20260486},
url = {https://europepmc.org/article/PMC/PMC13693304},
note = {CC BY},
}
RIS
TY - JOUR
TI - Female sexual dysfunction in anti-synthetase syndrome
AU - Lorenza Rosa Silvério da Silva
AU - Theo Lerner
AU - Elsa Aida Gay de Pereyra
AU - Alexandre Moura Dos Santos
AU - Samuel Katsuyuki Shinjo
PY - 2026
DA - 2026/10/23
JO - Revista da Associacao Medica Brasileira (1992)
DO - 10.1590/1806-9282.20260486
UR - https://europepmc.org/article/PMC/PMC13693304
AB - Objective Sexual dysfunction has not been investigated in women with anti-synthetase syndrome. The aim of this study was to determine the prevalence of sexual dysfunction in women with anti-synthetase syndrome compared with healthy controls (CTR), to evaluate associated clinical factors, and to assess the effect of cognitive behavioral therapy on sexual function and related outcomes.Methods This single-center study included a cross-sectional evaluation conducted between March and August 2023 and a prospective interventional phase. Thirty-three women with anti-synthetase syndrome and 31 CTR were included. Sexual function, sexual distress, quality of life, fatigue, depression, body image, physical activity, and disease-related parameters were assessed using validated questionnaires. Multivariate logistic regression was used to identify factors independently associated with sexual dysfunction. Patients with anti-synthetase syndrome and sexual dysfunction were invited to participate in group-based cognitive behavioral therapy, with up to 90 days' follow-up.Results Groups were comparable with respect to age and marital status. Sexual dysfunction prevalence was significantly higher in the anti-synthetase syndrome group than in CTR (81.8 vs. 51.6%; p=0.016). Anti-synthetase syndrome was independently associated with sexual dysfunction (OR 4.11; 95%CI 1.20-15.78). Within the anti-synthetase syndrome cohort, patients with and without sexual dysfunction were similar across most variables, except for prednisone use, which occurred only in patients with sexual dysfunction. Six patients completed cognitive behavioral therapy, showing improvements in sexual distress, sexual function-particularly arousal-and fatigue at 90 days.Conclusion Sexual dysfunction is highly prevalent in women with anti-synthetase syndrome and appears intrinsically associated with the disease. Cognitive behavioral therapy represents a promising non-pharmacological strategy to improve sexual function, distress, and fatigue in this population.
SN - 0104-4230
SN - 1806-9282
ER -